Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo
- PMID: 16641275
- PMCID: PMC1472065
- DOI: 10.1128/JVI.80.10.4833-4846.2006
Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo
Abstract
Kaposi's sarcoma-associated herpesvirus (KSHV) is associated with Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman's disease. Most KS tumor cells are latently infected with KSHV and are of endothelial origin. While PEL-derived cell lines maintain KSHV indefinitely, all KS tumor-derived cells to date have lost viral genomes upon ex vivo cultivation. To study KSHV latency and tumorigenesis in endothelial cells, we generated telomerase-immortalized human umbilical vein endothelial (TIVE) cells. TIVE cells express all KSHV latent genes 48 h postinfection, and productive lytic replication could be induced by RTA/Orf50. Similar to prior models, infected cultures gradually lost viral episomes. However, we also obtained, for the first time, two endothelial cell lines in which KSHV episomes were maintained indefinitely in the absence of selection. Long-term KSHV maintenance correlated with loss of reactivation in response to RTA/Orf50 and complete oncogenic transformation. Long-term-infected TIVE cells (LTC) grew in soft agar and proliferated under reduced-serum conditions. LTC, but not parental TIVE cells, formed tumors in nude mice. These tumors expressed high levels of the latency-associated nuclear antigen (LANA) and expressed lymphatic endothelial specific antigens as found in KS (LYVE-1). Furthermore, host genes, like those encoding interleukin 6, vascular endothelial growth factor, and basic fibroblast growth factor, known to be highly expressed in KS lesions were also induced in LTC-derived tumors. KSHV-infected LTCs represent the first xenograft model for KS and should be of use to study KS pathogenesis and for the validation of anti-KS drug candidates.
Figures
References
-
- Aluigi, M. G., A. Albini, S. Carlone, L. Repetto, R. De Marchi, A. Icardi, M. Moro, D. Noonan, and R. Benelli. 1996. KSHV sequences in biopsies and cultured spindle cells of epidemic, iatrogenic and Mediterranean forms of Kaposi's sarcoma. Res. Virol. 147:267-275. - PubMed
-
- An, F. Q., N. Compitello, E. Horwitz, M. Sramkoski, E. S. Knudsen, and R. Renne. 2005. The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus modulates cellular gene expression and protects lymphoid cells from p16 INK4A-induced cell cycle arrest. J. Biol. Chem. 280:3862-3874. - PubMed
-
- Bais, C., B. Santomasso, O. Coso, L. Arvanitakis, E. G. Raaka, J. S. Gutkind, A. S. Asch, E. Cesarman, E. A. Mesri, and M. C. Gershengorn. 1998. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391:86-89. - PubMed
-
- Ballestas, M. E., P. A. Chatis, and K. M. Kaye. 1999. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 284:641-644. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA109232/CA/NCI NIH HHS/United States
- R01 HL076810/HL/NHLBI NIH HHS/United States
- R01 DE018304/DE/NIDCR NIH HHS/United States
- CA110136/CA/NCI NIH HHS/United States
- CA109232/CA/NCI NIH HHS/United States
- CA88763/CA/NCI NIH HHS/United States
- CA73062/CA/NCI NIH HHS/United States
- R01 CA083134/CA/NCI NIH HHS/United States
- R01 CA088763/CA/NCI NIH HHS/United States
- HL076810/HL/NHLBI NIH HHS/United States
- R21 CA097939/CA/NCI NIH HHS/United States
- P5043703/PHS HHS/United States
- R03 CA110136/CA/NCI NIH HHS/United States
- R01 CA073062/CA/NCI NIH HHS/United States
- CA83134/CA/NCI NIH HHS/United States
- CA97939/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
